^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    CD22 (CD22 Molecule)

    i
    Other names: CD22, CD22 Molecule, CD22 Antigen, SIGLEC2, Sialic Acid-Binding Ig-Like Lectin 2, B-Lymphocyte Cell Adhesion Molecule, T-Cell Surface Antigen Leu-14, B-Cell Receptor CD22, SIGLEC-2, BL-CAM, Sialic Acid Binding Ig-Like Lectin 2, Siglec-2
    1d
    Antigen Targeted T Cell Therapy for Relapsed/Refractory B Cell Lymphomas (clinicaltrials.gov)
    P1/2, N=30, Recruiting, National University Hospital, Singapore | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD22 (CD22 Molecule)
    3d
    Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma (clinicaltrials.gov)
    P2, N=68, Active, not recruiting, Alliance for Clinical Trials in Oncology | Trial completion date: May 2028 --> May 2029 | Trial primary completion date: May 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    clonoSEQ
    |
    Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • prednisone • mercaptopurine • dexamethasone injection
    5d
    ALLight: Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=83, Recruiting, AstraZeneca
    Trial initiation date
    |
    CD22 (CD22 Molecule)
    |
    CD22 positive
    10d
    Analysis of ten cases of Acute lymphoblastic leukemia with non-KMT2A::AFF1 transcriptional variant 11q23 rearrangements (PubMed, Zhonghua Yi Xue Yi Chuan Xue Za Zhi)
    The 11q23 rearrangement ALL with non-KMT2A::AFF1 transcript is mainly KMT2A::MLLT1, T-ALL is more common, and the rate of chromosomal karyotype detection is relatively low. Persistent positive KMT2A-r is unfavorable for patient survival, and allo-HSCT during the CR1 period may improve patient survival.
    Retrospective data • Journal • IO biomarker
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • CD8 (cluster of differentiation 8) • KMT2A (Lysine Methyltransferase 2A) • CD38 (CD38 Molecule) • WT1 (WT1 Transcription Factor) • CD22 (CD22 Molecule) • AFF1 (AF4/FMR2 Family Member 1) • CD34 (CD34 molecule) • CD5 (CD5 Molecule) • MME (Membrane Metalloendopeptidase) • CD7 (CD7 Molecule) • MLLT3 (MLLT3 Super Elongation Complex Subunit) • CD2 (CD2 Molecule) • AFDN (Afadin, Adherens Junction Formation Factor) • FUT4 (Fucosyltransferase 4) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)
    |
    KMT2A rearrangement
    10d
    Chimeric antigen receptor T-cell therapies related to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: Diagnosis, high-risk factors, and management. (PubMed, Chin Med J (Engl))
    For management, we evaluate conventional therapies (corticosteroids, etoposide) and emerging immunomodulatory agents (anakinra, ruxolitinib, emapalumab), emphasizing the 2023 treatment regimen by the American Society of Transplantation and Cellular Therapy (ASTCT). By integrating risk stratification, early diagnostic criteria, and tailored therapeutic approaches, this review aims to improve clinical outcomes for IEC-HS patients.
    Journal • IO biomarker
    |
    TET2 (Tet Methylcytosine Dioxygenase 2) • IFNG (Interferon, gamma) • CD22 (CD22 Molecule) • CRP (C-reactive protein)
    |
    TET2 mutation
    |
    Jakafi (ruxolitinib) • etoposide IV • Kineret (anakinra)
    11d
    Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO) (clinicaltrials.gov)
    P2, N=25, Suspended, University of Chicago | Recruiting --> Suspended
    Trial suspension
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
    |
    dasatinib • Iclusig (ponatinib) • Besponsa (inotuzumab ozogamicin) • vincristine
    12d
    Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Peking University People's Hospital | N=30 --> 50 | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    cyclophosphamide • fludarabine IV
    14d
    A041703: Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=84, Recruiting, National Cancer Institute (NCI) | N=64 --> 84
    Enrollment change
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • CD22 (CD22 Molecule)
    |
    CD22 positive
    |
    Iclusig (ponatinib) • Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    14d
    Co-administration of CART22-65s and huCART19 for B-ALL (clinicaltrials.gov)
    P1/2, N=93, Recruiting, Stephan Grupp MD PhD | Trial completion date: Jan 2029 --> Jul 2029 | Trial primary completion date: Jan 2027 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    CD22 (CD22 Molecule)
    |
    CART22 • huCART19
    16d
    A roadmap for systematic humanization of a Chimeric Antigen Receptor: pre-clinical validation of a humanized CD22 scFv as a model. (PubMed, Exp Hematol)
    TEASER ABSTRACT: We developed a structure-guided humanization strategy for CD22-targeted CAR-T cells that preserves antigen binding while reducing immunogenicity. By grafting murine CDRs onto human frameworks and eliminating structural liabilities through in silico and biophysical screening, the resulting CARs maintained specificity and potency in vitro and in vivo, establishing a robust pipeline for next-generation CAR-T design.
    Preclinical • Journal
    |
    CD22 (CD22 Molecule)
    18d
    Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination. (clinicaltrials.gov)
    P2, N=30, Recruiting, Daihong Liu
    New P2 trial
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD22 (CD22 Molecule) • CD5 (CD5 Molecule)
    |
    TP53 mutation • CD22 positive
    |
    Epidaza (chidamide)
    24d
    International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (clinicaltrials.gov)
    P3, N=750, Not yet recruiting, Charite University, Berlin, Germany
    New P3 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)